Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

56 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Is it safe to discontinue primary Pneumocystis jiroveci pneumonia prophylaxis in patients with virologically suppressed HIV infection and a CD4 cell count <200 cells/microL?
Opportunistic Infections Project Team of the Collaboration of Observational HIV Epidemiological Research in Europe (COHERE); Mocroft A, Reiss P, Kirk O, Mussini C, Girardi E, Morlat P, Stephan C, De Wit S, Doerholt K, Ghosn J, Bucher HC, Lundgren JD, Chene G, Miro JM, Furrer H. Opportunistic Infections Project Team of the Collaboration of Observational HIV Epidemiological Research in Europe (COHERE), et al. Among authors: doerholt k. Clin Infect Dis. 2010 Sep 1;51(5):611-9. doi: 10.1086/655761. Clin Infect Dis. 2010. PMID: 20645862 Free article.
No need for secondary Pneumocystis jirovecii pneumonia prophylaxis in adult people living with HIV from Europe on ART with suppressed viraemia and a CD4 cell count greater than 100 cells/µL.
Atkinson A, Miro JM, Mocroft A, Reiss P, Kirk O, Morlat P, Ghosn J, Stephan C, Mussini C, Antoniadou A, Doerholt K, Girardi E, De Wit S, Kraus D, Zwahlen M, Furrer H; Opportunistic Infections Working Group of the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study in EuroCOORD. Atkinson A, et al. Among authors: doerholt k. J Int AIDS Soc. 2021 Jun;24(6):e25726. doi: 10.1002/jia2.25726. J Int AIDS Soc. 2021. PMID: 34118121 Free PMC article.
Children living with HIV in Europe: do migrants have worse treatment outcomes?
Chappell E, Kohns Vasconcelos M, Goodall RL, Galli L, Goetghebuer T, Noguera-Julian A, Rodrigues LC, Scherpbier H, Smit C, Bamford A, Crichton S, Navarro ML, Ramos JT, Warszawski J, Spolou V, Chiappini E, Venturini E, Prata F, Kahlert C, Marczynska M, Marques L, Naver L, Thorne C, Gibb DM, Giaquinto C, Judd A, Collins IJ; European Pregnancy and Paediatric Infections Cohort Collaboration (EPPICC). Chappell E, et al. HIV Med. 2022 Feb;23(2):186-196. doi: 10.1111/hiv.13177. Epub 2021 Oct 1. HIV Med. 2022. PMID: 34596323 Free PMC article.
Morbidity, mortality, and response to treatment by children in the United Kingdom and Ireland with perinatally acquired HIV infection during 1996-2006: planning for teenage and adult care.
Judd A, Doerholt K, Tookey PA, Sharland M, Riordan A, Menson E, Novelli V, Lyall EG, Masters J, Tudor-Williams G, Duong T, Gibb DM; Collaborative HIV Paediatric Study (CHIPS); National Study of HIV in Pregnancy and Childhood (NSHPC). Judd A, et al. Among authors: doerholt k. Clin Infect Dis. 2007 Oct 1;45(7):918-24. doi: 10.1086/521167. Epub 2007 Aug 27. Clin Infect Dis. 2007. PMID: 17806062
UK national clinical audit: management of pregnancies in women with HIV.
Raffe S, Curtis H, Tookey P, Peters H, Freedman A, Gilleece Y; British HIV Association Audit and Standards Sub-Committee. Raffe S, et al. BMC Infect Dis. 2017 Feb 20;17(1):158. doi: 10.1186/s12879-017-2255-6. BMC Infect Dis. 2017. PMID: 28219333 Free PMC article.
Differences in factors associated with initial growth, CD4, and viral load responses to ART in HIV-infected children in Kampala, Uganda, and the United Kingdom/Ireland.
Kekitiinwa A, Lee KJ, Walker AS, Maganda A, Doerholt K, Kitaka SB, Asiimwe A, Judd A, Musoke P, Gibb DM; Collaborative HIV Paediatric Study (CHIPS) Steering Committe; Mulago Cohort Team. Kekitiinwa A, et al. Among authors: doerholt k. J Acquir Immune Defic Syndr. 2008 Dec 1;49(4):384-92. doi: 10.1097/QAI.0b013e31818cdef5. J Acquir Immune Defic Syndr. 2008. PMID: 18931630
Prevalence, incidence, and associated risk factors of tuberculosis in children with HIV living in the UK and Ireland (CHIPS): a cohort study.
Turkova A, Chappell E, Judd A, Goodall RL, Welch SB, Foster C, Riordan A, Shingadia D, Shackley F, Doerholt K, Gibb DM, Collins IJ; Collaborative HIV Paediatric Study (CHIPS) Steering Committee. Turkova A, et al. Among authors: doerholt k. Lancet HIV. 2015 Dec;2(12):e530-9. doi: 10.1016/S2352-3018(15)00200-3. Epub 2015 Oct 29. Lancet HIV. 2015. PMID: 26614967
Lopinavir dosing in HIV-infected children in the United Kingdom and Ireland.
Donegan K, Doerholt K, Judd A, Lyall H, Menson E, Butler K, Tookey P, Riordan A, Shingadia D, Tudor-Williams G, Gibb DM, Walker AS; Collaborative HIV Paediatric Study (CHIPS). Donegan K, et al. Among authors: doerholt k. Pediatr Infect Dis J. 2013 Jan;32(1):45-50. doi: 10.1097/INF.0b013e31827842c9. Pediatr Infect Dis J. 2013. PMID: 23076384
HIV-1 drug resistance in HIV-1-infected children in the United Kingdom from 1998 to 2004.
Chakraborty R, Smith CJ, Dunn D, Green H, Duong T, Doerholt K, Riordon A, Lyall H, Tookey P, Butler K, Sabin CA, Gibb D, Pillay D; Collaborative HIV Paediatric Study; UK Collaborative Group on HIV Drug Resistance. Chakraborty R, et al. Among authors: doerholt k. Pediatr Infect Dis J. 2008 May;27(5):457-9. doi: 10.1097/INF.0b013e3181646d6f. Pediatr Infect Dis J. 2008. PMID: 18382385
56 results